ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals

9th September 2017 Uncategorised 0

Right now, Merck’s Keytruda is the only PD-1/PD-L1 med with data to show it can improve overall survival in the second-line bladder cancer setting. And it keeps piling it on.

More: ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals
Source: fierce